Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Michael Rühlmann"'
Autor:
Cordula Leonie Merle, Robin Hoffmann, Jan Schmickler, Michael Rühlmann, Nadia Challakh, Rainer Haak, Gerhard Schmalz, Dirk Ziebolz
Publikováno v:
Journal of Clinical Medicine
Journal of Clinical Medicine, Vol 9, Iss 2, p 513 (2020)
Journal of Clinical Medicine, Vol 9, Iss 2, p 513 (2020)
Background: The aim of this cross-sectional study was to investigate oral health and functional status of adolescents with juvenile idiopathic arthritis (JIA) and its possible link to disease specific parameters. Methods: Patients with JIA were recru
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::3c84996d657c478cd52497ed350c3ba3
http://europepmc.org/articles/PMC7074230
http://europepmc.org/articles/PMC7074230
Autor:
Andreas Urban, Toni Hospach, W. Emminger, Ariane Klein, Eggert Lilienthal, Ralf Trauzeddel, Michael Rühlmann, Gerd Horneff, Frank Dressler, Christoph Rietschel, Markus Hufnagel, Michaela Sailer-Hoeck, Georg Heubner, Tilmann Kallinich, Frank Weller-Heinemann, Gerd Ganser
Publikováno v:
Paediatric rheumatology.
Background Canakinumab is approved for the treatment of systemic juvenile idiopathic arthritis (sJIA) older than 2 years. Objectives The aim of the German Biologics Registry (BiKeR) is the surveillance of JIA patients exposed to biologics. Methods Ba
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8b19cbfbb169fb4dae52d38f0007a862
https://doi.org/10.1136/annrheumdis-2019-eular.1429
https://doi.org/10.1136/annrheumdis-2019-eular.1429
Autor:
S. Mrusek, Ivan Foeldvari, Gerd Ganser, Kirsten Minden, Toni Hospach, Frank Dressler, Michael Rühlmann, Boris Huegle, Andreas Urban, Frank Weller-Heinemann, Jasmin B Kuemmerle-Deschner, Gerd Horneff, Ariane Klein, Ralf Trauzeddel
Publikováno v:
Poster Presentations.
Background Since 2000, Etanercept is approved for polyarticular juvenile idiopathic arthritis (JIA). Subsequently, approval has been extended to additional JIA categories. Objectives To describe efficacy and safety of Etanercept in clinical practice
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::045ae2deae39685c217e2f2c125cab87
https://doi.org/10.1136/annrheumdis-2019-eular.1568
https://doi.org/10.1136/annrheumdis-2019-eular.1568
Publikováno v:
Annals of the Rheumatic Diseases. 80:98.1-98
Background:In 2017, 2 Etanercept biosimilars became approved. Comparative studies performed in adult patients with rheumatoid arthritis, ankylosing spondylitis or psoriasis by extrapolation led to approval for juvenile idiopathic arthritis (JIA).Obje
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3b077e79f1cf413ce6335bf48e60e0b5
https://doi.org/10.1136/annrheumdis-2021-eular.1003
https://doi.org/10.1136/annrheumdis-2021-eular.1003
Publikováno v:
Annals of the Rheumatic Diseases. 80:933.2-934
Background:In 2017, Adalimumab Biosimilars became approved. Comparative studies to the originator have been performed in adult patients with rheumatoid arthritis, ankylosing spondylitis and psoriasis and extrapolation led to approval for juvenile idi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::44a9baa9f166d0df6da524bba8314f2b
https://doi.org/10.1136/annrheumdis-2021-eular.1433
https://doi.org/10.1136/annrheumdis-2021-eular.1433